about
The IDOL-UBE2D complex mediates sterol-dependent degradation of the LDL receptorSynthetic LXR ligand inhibits the development of atherosclerosis in miceApoE promotes the proteolytic degradation of AbetaLXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptorLiver X receptors at the intersection of lipid metabolism and atherogenesisReciprocal regulation of inflammation and lipid metabolism by liver X receptorsDirect and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptorsTranscription of the vascular endothelial growth factor gene in macrophages is regulated by liver X receptorsFeedback modulation of cholesterol metabolism by the lipid-responsive non-coding RNA LeXisLigand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoEConstitutive activation of LXR in macrophages regulates metabolic and inflammatory gene expression: identification of ARL7 as a direct targetPalmoplantar keratoderma along with neuromuscular and metabolic phenotypes in Slurp1-deficient miceInhibition of adipocyte differentiation by Nur77, Nurr1, and Nor1IDOL stimulates clathrin-independent endocytosis and multivesicular body-mediated lysosomal degradation of the low-density lipoprotein receptor.Palmoplantar Keratoderma in Slurp2-Deficient MiceThe macrophage LBP gene is an LXR target that promotes macrophage survival and atherosclerosis.LXR deficiency confers increased protection against visceral Leishmania infection in mice.2014 American Society for Clinical Investigation Presidential Address. Leading by example: pastors, mentors, physician-scientists, and the ASCI.An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain CancersThe E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2.Transgenic expression of dominant-active IDOL in liver causes diet-induced hypercholesterolemia and atherosclerosis in mice.The small molecule phenamil is a modulator of adipocyte differentiation and PPARgamma expressionLiver x receptor signaling pathways and atherosclerosis.Dietary cholesterol promotes adipocyte hypertrophy and adipose tissue inflammation in visceral, but not in subcutaneous, fat in monkeys.Identification of macrophage liver X receptors as inhibitors of atherosclerosis.GPIHBP1, an endothelial cell transporter for lipoprotein lipase.Cholesterol intake modulates plasma triglyceride levels in glycosylphosphatidylinositol HDL-binding protein 1-deficient mice.Vestigial-like 3 is an inhibitor of adipocyte differentiation.LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression.Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli.Regulation of macrophage inflammatory gene expression by the orphan nuclear receptor Nur77.PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism.Critical Roles of the Histone Methyltransferase MLL4/KMT2D in Murine Hepatic Steatosis Directed by ABL1 and PPARγ2.Orphan nuclear receptors find a home in the arterial wall.Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease.The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesionsResistance to diet-induced obesity in mice with synthetic glyoxylate shuntTargeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists.LXRs: new therapeutic targets in atherosclerosis?Liver X receptor signaling pathways in cardiovascular disease.
P50
Q24306758-DE48EE34-6956-491A-9408-5C711AB3259FQ24530617-9348153B-C617-4479-8374-D05520937A3DQ24651102-A31C6539-4B74-4747-8976-3BD85BB695D5Q24656186-311D67FF-3DA0-4C82-B6FC-93DFB19CCEB2Q28082452-DDC7C253-E803-4FE2-9142-F91F106BB60BQ28202771-88F53726-93F0-4503-A833-8EE026982501Q28215527-8382A49E-FF29-45DB-8633-D70E3D1C99B8Q28236615-641EC7E0-8EDD-41CD-A3F5-4A8456DF8D31Q28512190-0D28EF42-C029-449E-917C-1DF243EA49A3Q28513193-C3135872-84C6-4B92-A15C-B0BB66DA46AEQ28588828-7527D2E5-0467-4363-8179-3FD571F8A4C0Q28589893-CEB37A46-A462-4E80-AA5E-E1EB9BE310F2Q28591002-13FB1F9E-B595-48F4-9AC8-26951347FB1EQ30538763-D8F0D006-E587-459A-B50A-9B6A093E6D8DQ30665199-AF3E1C23-3BDB-4CDC-9455-D873AFA4317DQ33653635-D30BFFE8-F0EF-4B1B-9681-C700F0D5C43EQ33754665-30A991B0-6BE5-442A-8F14-046C872012EDQ33808315-B6C719E2-0A8E-4BF7-A308-E38661CA6AC0Q33822099-25003569-1C3F-43E7-8448-AA54EC433500Q33924208-BAC0BA1D-E6F5-4C77-AAB1-CD66C8770FF8Q33992107-43336FCF-3683-453C-987F-DC1690188E11Q34053176-3C2BD456-A0D8-4665-A90D-E6ABB4E95B3BQ34056326-2C83D718-97F3-4A30-9317-B5AA5066C459Q34076091-32B98FD9-ECAE-4134-AE29-32D8A4D4D299Q34154665-ACBAAD61-0948-41CB-92CF-4746A3569345Q34208235-60C1219A-0931-4E3E-AB76-E39C6B3BED03Q34222252-842D49DC-9B76-44A3-B8E9-195087134A8AQ34311845-3D9C9C86-E655-48F4-8AF3-E682698F106DQ34360087-7E7E532C-A128-4B07-8A5B-7EC89D6D6049Q34427465-AE3C1804-1749-4E19-BF22-0C85B0F8F560Q34474472-6BA57AAF-6192-42AF-9249-448176860513Q34542321-92B7134A-FE71-43FF-83E4-683609EE0E7AQ34543956-1C4162BC-9927-4796-9109-5B28832EFEEFQ34586834-2B289B19-B5B7-4AA5-903D-A837A00F147AQ34629103-511A4A53-43ED-413D-ABDB-969BFFE075F5Q34740387-0D2821F2-2751-410F-97CD-961F496F1D93Q34778767-1A0E0A8A-4AFB-4B20-B386-319A4412D87AQ35096270-CB958923-F9EA-4434-8C46-ABC484156F9FQ35101722-CD932680-1328-43C3-9B16-DCA4134C1E83Q35104848-0CD1074C-DF75-4DBD-ADC4-A3C446326BDE
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Peter Tontonoz
@ast
Peter Tontonoz
@en
Peter Tontonoz
@es
Peter Tontonoz
@nl
Peter Tontonoz
@pt
type
label
Peter Tontonoz
@ast
Peter Tontonoz
@en
Peter Tontonoz
@es
Peter Tontonoz
@nl
Peter Tontonoz
@pt
prefLabel
Peter Tontonoz
@ast
Peter Tontonoz
@en
Peter Tontonoz
@es
Peter Tontonoz
@nl
Peter Tontonoz
@pt
P106
P21
P31
P496
0000-0003-1259-0477